Answers are grounded in this paper and cite their sources.
Diabetic kidney disease (DKD) lacks effective therapies that halt disease progression. Although oxidative stress-induced DNA damage in tubular epithelial cells contributes to disease progression, its upstream regulatory mechanisms remain poorly defined. Here, we identify nucleoside diphosphate kinase 1 (NME1) as a key regulator of the DNA damage response (DDR) and a direct target of ovatodiolide (OVA). Proteome-wide and structural analyses reveal that OVA binds NME1 at Lys12 and Arg114 and interferes with its interaction with the E3 ubiquitin ligase TRIM47, thereby suppressing NME1 ubiquitination and proteasomal degradation. Stabilized NME1 interacts with BRAT1 to facilitate assembly of the BRAT1-ATM complex, leading to activation of ATM-dependent DNA repair signaling. Functionally, OVA reduces reactive oxygen species accumulation and DNA damage in tubular epithelial cells through an NME1-dependent mechanism that requires BRAT1-mediated ATM activation. In diabetic mice, OVA ameliorates renal injury independently of glycemic control, whereas tubular NME1 silencing abrogates these effects. Notably, the optimized derivative ACT004 retains NME1-dependent cytoprotective activity with reduced cytotoxicity. Collectively, these findings demonstrate that OVA suppresses TRIM47-mediated NME1 ubiquitination to restore BRAT1-ATM-dependent DNA repair signaling and highlight pharmacological stabilization of NME1 as a potential therapeutic strategy for DKD.
No takes yet. Share an insight, caveat, or question.
Long et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: